DCPH Stock Forecast: 2022, 2023, 2024, 2025, 2030

Deciphera Pharmaceuticals news highlights that during the early trading session on Friday, Deciphera Stock price was down 71.6 percent at $10.24.

The shares of Deciphera Pharmaceuticals Inc, Deciphera Pharmaceuticals Stock, fell to a 52-week low after the company announced unsatisfactory findings from the INTRIGUE Phase 3 research of Qinlock in patients with gastrointestinal stromal tumor (GIST) who had recently been treated with Novartis AG’s (NYSE: NVS) Gleevec.

How Many Employees Does Deciphera Pharmaceuticals Have?

The company of Deciphera Pharmaceuticals Stock has 441 employees.

When Did Deciphera Go Public?

According to official DCPH News, on September 27, 2017, Deciphera Pharmaceuticals, Inc. (Deciphera Pharmaceuticals Stock), a clinical-stage biopharmaceutical firm focused on solving key mechanisms of tumor drug resistance, revealed the pricing of its initial public offering of 7,500,000 shares of common stock, Deciphera Pharmaceuticals Stock, at a public offering price (Deciphera Stock price) of $17.00 per share for aggregate gross proceeds of $127,500,000.

When Was Deciphera Founded?

Company of Deciphera Pharmaceuticals Stock was founded in 2003.

Why Is Deciphera Stock Price Increased 70%?

When a stock falls by 75% in a short period of time, traders have cause to worry. When such a change is detected during a trading day, it’s time to make a noise. Such tends to be the present situation for Deciphera Pharmaceuticals Stock (NASDAQ:DCPH) and DCPH stock investors, as per the Deciphera Pharmaceuticals news.

This tremendous daily movement in Deciphera Stock price is noteworthy for a number of reasons, as it seen on the Deciphera Pharmaceuticals news. Up until today, Deciphera Pharmaceuticals Stock has had some very good momentum over the previous month. This was a biopharmaceutical stock with a lot of interest.

It is significant that the firm is focused on improving the lives of people with cancer by improving the durability of reaction and addressing other important difficulties that afflict cancer medications. This is a corporation on a goal to change the world. And Deciphera is hopeful that their QINLOCK therapy for gastrointestinal (GI) tumors will be the cure the pharmaceutical industry has been looking for.

14 Days Historical Data of Deciphera Stock Price

What Does Deciphera Pharmaceuticals Do?

Deciphera Pharmaceuticals, Inc. is a pharmaceutical firm that produces medications to improve the lives of people with cancer by targeting critical aspects of drug resistance that restrict the rate and duration of response to recent cancer treatments. Its principal therapeutic target is QINLOCK, which is being studied in the INTRIGUE Phase 3 research to treat second-line gastrointestinal stromal tumors (GIST).

The business is also working to develop immunokinase inhibitors, including vimseltinib (DCC-3014), that’s in a Stage 1b/2 medical study for the therapies of tenosynovial giant cell tumors, and Rebastinib, that is in a Stage 1b/2 medical study for the treatment of metastatic solid tumors, and also for use in combination with chemotherapy for the treatment of multiple solid tumors. Furthermore, DCC-3116 is being tested in preclinical studies to cure RAS/RAF mutant tumors. The business has operations in both the United States and Europe. Deciphera Pharmaceuticals, Inc., based in Waltham, Massachusetts, was formed in 2003.

DCPH News

The Deciphera Pharmaceuticals Stock (NASDAQ: DCPH) fell to a 52-week low after the company announced unsatisfactory findings from the INTRIGUE Phase 3 trial of Qinlock in people with gastrointestinal stromal tumor (GIST) who had recently been treated with Novartis AG’s (NYSE: NVS) Gleevec (imatinib).

On the Deciphera Pharmaceuticals news, it is highlighted that the main goal of increased progression-free survival (PFS) compared to the quality of care Pfizer Inc’s (NYSE: PFE) Sutent was not met. The entire findings of the INTRIGUE Phase 3 clinical trial will be published at a future medical symposium.

453 individuals were randomly assigned to receive either Qinlock 150 mg once daily or sunitinib 50 mg once day for four weeks, linked to two weeks without sunitinib.

The main outcome objective of progression-free survival (PFS) was not met in this trial.

Qinlock revealed a median PFS (mPFS) of 8.3 months in patients with a KIT exon 11 main mutation (n=327) comparing to 7.0 months in the sunitinib arm.

Even though not technically assessed because of the hierarchical testing sequence restrictions, Qinlock revealed a mPFS of 8.0 in the all patient intent-to-treat (AP) sample.

DCPH Stock Forecast

According to Deciphera price predictions, Deciphera Pharmaceuticals’ anticipated yearly profits growth rate of N/A is not expected to outperform the US Biotechnology industry’s average DCPH Stock Forecast earnings growth rate of 35.51 percent, nor is it expected to outperform the US market’s average DCPH Stock Forecast earnings growth rate of 16.15 percent. In 2021, Deciphera Pharmaceuticals’ profits will be -$274,309,000. As per the DCPH Stock Forecast for 2021, the stock price is expected to be $-285,386,485, with the lowest DCPH Stock Forecast at $-295,913,035 and the highest DCPH Stock Forecast at $-274,859,934.

DCPH Stock Forecast for the next days and 2021, 2022, 2023, 2024, 2025, 2026:

DCPH Stock Forecast data:

• Current Deciphera Stock price is 8.810 USD.
• The Deciphera Stock price can increase from 8.810 USD to 18.855 USD in one year, as per the Deciphera price predictions.
• 52-week high Deciphera price prediction is 44.851 USD.
• 52-week low Deciphera price prediction is 12.492 USD.
• 45-Day Moving Average of Deciphera price predictions is 40.597 USD.
• 90-Day Moving Average of Deciphera price predictions is 39.348 USD.
• According to the Deciphera price prediction 2021, 2022, 2023, 2024, 2025, 2030 charts, the long-term profit potential is +114.02% in one year.

Below you can check the Deciphera price predictions for 2021, 2022, 2023, 2024, 2025, 2030.

DCPH Stock Forecast 2021

• As per the 5 Wall Street experts offering 12 month DCPH Stock Forecast chart and Deciphera price predictions in the last 3 months, the average Deciphera price prediction is $67.00 with a high DCPH Stock forecast of $70.00 and a low DCPH Stock forecast of $60.00.